Back to Stakeholders

Columbia University Irving Medical Center (CUIMC) is a major academic medical centre in New York City, integrating Columbia University's Vagelos College of Physicians and Surgeons with NewYork-Presbyterian Hospital and conducting research across neuroscience, psychiatry, and translational medicine. CUIMC serves as the primary clinical site for the Ketamine Biomarker Validation trial (NCT07307768), an EEG-based Phase I study examining dose-response relationships across three ketamine infusion levels in adults with treatment-resistant major depressive disorder.

Academic Research

0 papers

Published Papers

0

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Unknown

Clinical Care Delivery Snapshot

Health Systems & Hospitals

Provider Model

Health System / Hospital Program

Organization Status

Unknown

Psychedelic Services

Unknown

Service Coverage

Global

Service Profile

Care Settings

Hospital Outpatient

Payer Models

Unknown

Non-Psychedelic Service Mix

Unknown

Visit Provider

Care Delivery Notes

Backfilled profile for existing L2 clinical care delivery stakeholder.

Quick Facts

Type
Other
HQ
United States
Website
Visit

Collaborated Trials

1